FOIU 2018: Ureteoscopic Management of Upper Tract UC: Time to Update the Guidelines?

Tel-Aviv, Israel ( Scott Hubosky, MD, began his talk with the change that the current European Urology guidelines have made regarding the indication for kidney preservation treatment for low-grade upper tract urothelial carcinoma (UTUC). The change from 2015 to 2018 is that the upper limit of tumor size increased from 1 cm to 2 cm. Dr. Hubosky recommends a risk-adapted strategy for kidney-sparing management of upper tract tumors.

FOIU 2018: Experience with Mitogel in Upper Tract Urothelial Carcinoma

Tel-Aviv, Israel ( Nir Kleinman, MD gave a talk on the use of Mitogel in upper tract urothelial carcinoma (UTUC). He began with a short overview of UTUC. This is a tumor representing 5-7% of all renal tumors, and 5% of all urothelial carcinomas. The peak incidence is between ages 75-79. Radical nephroureterectomy (RNU) is the standard of care treatment for UTUC, and can be performed either open, robotically, or laparoscopically. Unfortunately, RNU can have serious implications, including chronic kidney disease and dialysis, cardiovascular disease, hospitalizations, and recurrence in the contralateral kidney. 

FOIU 2018: Lynch Syndrome and Upper Tract Urothelial Carcinoma

Tel-Aviv, Israel ( Scott Hubosky, MD gave an overview of Lynch syndrome and its association with upper tract urothelial carcinoma (UTUC).  Lynch syndrome is an autosomal dominant hereditary nonpolyposis colorectal cancer syndrome. The defects are in DNA mismatch repair (MMR) genes (MSH2, MKH1, MSH6, PMS2). It is associated with a higher lifetime risk of various cancers, including colon, endometrial, and UTUC.